Patents by Inventor Johannes Scheid

Johannes Scheid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof
    Publication number: 20230365661
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: February 22, 2023
    Publication date: November 16, 2023
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
    Publication number: 20230192823
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 22, 2023
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Human immunodeficiency virus neutralizing antibodies and methods of use thereof
    Patent number: 11634478
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 25, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
    Patent number: 11472868
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 18, 2022
    Assignees: CALIFORNIA INSTITUTE OF TECHNOLOGY, THE ROCKEFELLER UNIVERSITY
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
    Publication number: 20220002391
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 6, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits
    Patent number: 11155605
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: October 26, 2021
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210230254
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: January 11, 2021
    Publication date: July 29, 2021
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Human immunodeficiency virus neutralizing antibodies and methods of use thereof
    Patent number: 10889633
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 12, 2021
    Assignees: The Rockefeller University, California Institute of Technoloqy
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
    Publication number: 20200165325
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: February 10, 2020
    Publication date: May 28, 2020
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
    Publication number: 20200140528
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Application
    Filed: September 23, 2019
    Publication date: May 7, 2020
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120
    Patent number: 10590187
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 17, 2020
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
    Patent number: 10421803
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 24, 2019
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
    Publication number: 20180237506
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 23, 2018
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel C. Nussenzweig, Johannes Scheid
  • Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
    Publication number: 20180171001
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 21, 2018
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Human Immunodeficiency Virus Neutralizing Antibodies and Methods of Use Thereof
    Publication number: 20180079800
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 22, 2018
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
    Patent number: 9890207
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: February 13, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Human immunodeficiency virus neutralizing antibodies and methods of use thereof
    Patent number: 9783594
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: October 10, 2017
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
    Patent number: 9493549
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 15, 2016
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140328862
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: May 17, 2012
    Publication date: November 6, 2014
    Applicants: THE ROCKEFELLER UNIVERSITY, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
    Patent number: 8673307
    Abstract: Broad neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV, especially the preparation and use of highly neutralizing antibodies directed to HIV gp120 envelope protein, in the vaccination and treatment of HIV-infected patients.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: March 18, 2014
    Assignee: The Rockefeller University
    Inventors: Michel C. Nussenzweig, Johannes Scheid, John Pietzsch